Fathom Therapeutics

Based in the US, Fathom Therapeutics specializes in advanced molecular solutions that tackle critical challenges in drug development and biotechnology, enhancing molecular analysis for improved therapeutic discovery and diagnostics. Fathom Therapeutics, founded in 2023 and headquartered in New York, US, focuses on molecular technologies for drug development and biotechnology. The company has successfully completed 3 deals, with its most recent funding round being a Series A in April 2026, raising USD 47. 00 mn led by Sutter Hill Ventures.

Other investors include Alexandria Venture Investments, Chemistry, and New York Ventures. The founder's history and previous companies are not publicly mentioned. Fathom Therapeutics specializes in advanced molecular solutions designed to address significant challenges in drug development and biotechnology. Their core product offerings feature proprietary technologies that enhance molecular analysis, enabling researchers and pharmaceutical companies to streamline workflows and improve the accuracy of their findings.

These technologies are utilized in therapeutic discovery, diagnostics, and personalized medicine, serving clients in the healthcare and life sciences sectors, including biopharmaceutical firms and academic research institutions across North America, Europe, and parts of Asia. Fathom Therapeutics generates revenue through a structured model involving direct partnerships with B2B clients. Transactions are typically based on subscription access to its molecular technologies, allowing clients to utilize advanced tools for research and development. The company also engages in collaborative projects with pharmaceutical firms that include milestone payments tied to research progress.

Their pricing structure is aligned with the value provided, offering tiered plans for various scales of research operations. In April 2026, Fathom Therapeutics raised USD 47. 00 mn in Series A funding to support its product development and expansion plans. The funding will be utilized to develop new products aimed at further enhancing their molecular technologies.

The company is also targeting expansion into new markets, specifically in Europe and parts of Asia, by 2027 to broaden its customer base and enhance its global presence.